Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jun;73(11):1373–1380. doi: 10.1038/bjc.1996.261

Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide.

T Asano 1, L A Zwelling 1, T An 1, A McWatters 1, C E Herzog 1, J Mayes 1, S M Loughlin 1, E S Kleinerman 1
PMCID: PMC2074495  PMID: 8645582

Abstract

The human brain tumour cell line HBT20 is intrinsically resistant to etoposide and does not express mdr-1 mRNA. These studies were conducted to determine whether transfecting a Drosophila (D) topoisomerase II (topo II) gene into HBT20 cells could increase their sensitivity to etoposide. A D-topo II construct in a pMAMneo vector under the control of a mouse mammary tumour virus (MMTV) promoter was transfected into HBT20 cells. The gene is inducible by dexamethasone (Dex). The growth rate of the transfected cells and percentage of the cells in G1, S and G2M was no different than the parental cells. Survival after etoposide exposure (10 microM x 2 h) was measured by colony formation. Parental cells and cells transfected by pMAMneo vector alone showed no enhanced etoposide sensitivity after 24 h of Dex stimulation. By contrast, D-topo II transfected cells were sensitised 3-fold when etoposide treatment was preceded by 24 h Dex stimulation. Northern blotting and Western blotting confirmed that Dex had induced D-topo II expression in the sensitised cells. However, in D-topo II-transfected cells increasing the duration of Dex stimulation to 48 h eliminated the sensitisation to etoposide although increased MMTV promoter activity and expression of the D-topo II gene persisted. Measurement of endogenous human topo-II mRNA and protein revealed a decrease after Dex exposure of greater than 24 h. At these distal times, the total cellular topo II levels (endogenous + exogenous) may be decreased, which may explain why increased sensitivity to etoposide could no longer be demonstrated. This model suggests that D-topo II gene transfection can sensitise de novo resistant HBT20 cells to etoposide but that the time frame of that sensitisation is limited.

Full text

PDF
1373

Images in this article

1375Figure 1
on p.1375
1375Figure 2
on p.1375
1376Figure 3
on p.1376
1378Figure 5
on p.1378

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bugg B. Y., Danks M. K., Beck W. T., Suttle D. P. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7654–7658. doi: 10.1073/pnas.88.17.7654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Campain J. A., Gottesman M. M., Pastan I. A novel mutant topoisomerase II alpha present in VP-16-resistant human melanoma cell lines has a deletion of alanine 429. Biochemistry. 1994 Sep 20;33(37):11327–11332. doi: 10.1021/bi00203a030. [DOI] [PubMed] [Google Scholar]
  3. Chan V. T., Ng S. W., Eder J. P., Schnipper L. E. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line. J Biol Chem. 1993 Jan 25;268(3):2160–2165. [PubMed] [Google Scholar]
  4. Eder J. P., Jr, Chan V. T., Niemierko E., Teicher B. A., Schnipper L. E. Conditional expression of wild-type topoisomerase II complements a mutant enzyme in mammalian cells. J Biol Chem. 1993 Jul 5;268(19):13844–13849. [PubMed] [Google Scholar]
  5. Gewirtz D. A. Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors? Biochem Pharmacol. 1991 Nov 27;42(12):2253–2258. doi: 10.1016/0006-2952(91)90227-v. [DOI] [PubMed] [Google Scholar]
  6. Herzog C. E., Zwelling L. A., McWatters A., Kleinerman E. S. Expression of topoisomerase II, bcl-2, and p53 in three human brain tumor cell lines and their possible relationship to intrinsic resistance to etoposide. Clin Cancer Res. 1995 Nov;1(11):1391–1397. [PubMed] [Google Scholar]
  7. Hsiang Y. H., Liu L. F. Evidence for the reversibility of cellular DNA lesion induced by mammalian topoisomerase II poisons. J Biol Chem. 1989 Jun 15;264(17):9713–9715. [PubMed] [Google Scholar]
  8. Kaufmann S. H., Karp J. E., Jones R. J., Miller C. B., Schneider E., Zwelling L. A., Cowan K., Wendel K., Burke P. J. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood. 1994 Jan 15;83(2):517–530. [PubMed] [Google Scholar]
  9. Kaufmann S. H., McLaughlin S. J., Kastan M. B., Liu L. F., Karp J. E., Burke P. J. Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res. 1991 Jul 1;51(13):3534–3543. [PubMed] [Google Scholar]
  10. Liu L. F. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 1989;58:351–375. doi: 10.1146/annurev.bi.58.070189.002031. [DOI] [PubMed] [Google Scholar]
  11. Liu Y. X., Hsiung Y., Jannatipour M., Yeh Y., Nitiss J. L. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide. Cancer Res. 1994 Jun 1;54(11):2943–2951. [PubMed] [Google Scholar]
  12. Minford J., Pommier Y., Filipski J., Kohn K. W., Kerrigan D., Mattern M., Michaels S., Schwartz R., Zwelling L. A. Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II. Biochemistry. 1986 Jan 14;25(1):9–16. doi: 10.1021/bi00349a002. [DOI] [PubMed] [Google Scholar]
  13. Ritke M. K., Roberts D., Allan W. P., Raymond J., Bergoltz V. V., Yalowich J. C. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells. Br J Cancer. 1994 Apr;69(4):687–697. doi: 10.1038/bjc.1994.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Robinson M. J., Osheroff N. Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II. Biochemistry. 1991 Feb 19;30(7):1807–1813. doi: 10.1021/bi00221a012. [DOI] [PubMed] [Google Scholar]
  15. Schneider E., Horton J. K., Yang C. H., Nakagawa M., Cowan K. H. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res. 1994 Jan 1;54(1):152–158. [PubMed] [Google Scholar]
  16. Spitzner J. R., Muller M. T. A consensus sequence for cleavage by vertebrate DNA topoisomerase II. Nucleic Acids Res. 1988 Jun 24;16(12):5533–5556. doi: 10.1093/nar/16.12.5533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Takano H., Kohno K., Ono M., Uchida Y., Kuwano M. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res. 1991 Aug 1;51(15):3951–3957. [PubMed] [Google Scholar]
  18. Wasserman R. A., Wang J. C. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine. Cancer Res. 1994 Apr 1;54(7):1795–1800. [PubMed] [Google Scholar]
  19. Webb C. D., Latham M. D., Lock R. B., Sullivan D. M. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res. 1991 Dec 15;51(24):6543–6549. [PubMed] [Google Scholar]
  20. Zwelling L. A., Hinds M., Chan D., Mayes J., Sie K. L., Parker E., Silberman L., Radcliffe A., Beran M., Blick M. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II. J Biol Chem. 1989 Oct 5;264(28):16411–16420. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES